2024 International Congress » Parkinson’s Disease: Pharmacology and Therapy

A case of malignant Deep Brain Stimulation Withdrawal Syndrome treated with Opicapone

D. Brogle, L. Zünd-Hofer, F. Brugger, G. Kägi (Sankt Gallen, Switzerland)

A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion

G. Lazzeri, C. Baiata, F. Del Sorbo, M. Corradi, M. Barichella, L. Caffi, C. Palmisano, P. Soliveri, G. Pezzoli, IU. Isaias (Milan, Italy)

A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi

M. Gwedela, T. Phiri (Blantyre, Malawi)

A Quantitative Investigation has Revealed Nifedipine as a Possible Pharmacological Modulator in Parkinson’s Disease

G. Kuanar, C. Mahapatra (Cuttack, India)

AAV-mediated gene therapy for GBA-PD

S. Ayloo, J. Ryu, S. Chou, C. Miller, L. Blatnik, E. Wischhof, J. Bu, W. Mccarty, L. Guo, S. Nass, C. O'Riordan, B. Elmer, C. Mueller, S. Ramachandran (Waltham, USA)

Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data

R. Joseph, J. Qian, H. Cummings, Y. Chen, S. Tewari, M. Soileau (Columbus, USA)

Aerobic Exercise in Non-Exercisers with Advanced Parkinson’s Disease (PD) and Deep Brain Stimulation (DBS): A Pilot Study

S. Aslam, M. Olson, S. Felson, F. Ponce, H. Shill (Aurora, USA)

An observational study of the efficacy, safety, and discontinuation rate of foslevodopa/foscarbidopa in 22 patients with advanced Parkinson’s disease

D. Kamiyama, N. Nishikawa, C. Abe, H. Iwaki, G. Oyama, T. Hatano, N. Hattori (Bunkyo, Japan)

Antipsychotic Prescriptions Among Nursing Home Residents with Parkinson’s Disease in the End-of-Life Period

S. Berman, A. Willis, W. Aamodt (Philadelphia, USA)

Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease

XD. Yang, Q. Xiao, XQ. He (Shanghai, China)

Association between statin use and mortality in Parkinson’s disease

M. Park, I. Hong, M. Baek (Gwangmyeong, Republic of Korea)

Attitudes and Beliefs Towards Medication Burden and Deprescribing in Parkinson Disease

TP. Pham Nguyen, D. Thibault, A. Hamedani, A. Willis (Philadelphia, USA)

Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain

D. Saturnino Guarino, G. Tian, K. Ho Young, H. Cj, V. Lee, K. Luk, R. Mach (Philadelphia, USA)

Baseline Variables Associated with Apomorphine Sublingual Film Retention

J. Kassubek, J. Schwarz, L. López Manzanares, M. Fonseca, C. Denecke Muhr (Ulm, Germany)

Beta peaks as predictor for DBS outcome in Parkinson’s disease

V. Molinari, M. Sure, E. Florin, C. Hartmann, A. Schnitzler (Düsseldorf, Germany)

Bidirectional interplay between DBS and cognition in Parkinson’s disease: a systematic review

V. Sisodia, A. Malekzadeh, E. Verwijk, P. Schuurman, R. de Bie, B. Swinnen (Amsterdam, Netherlands)

Bioreactor-produced iPSCs-derived Dopaminergic Neuron-containing Neural Microtissues Innervate and Restore Motor Function in a Dose-dependent Manner in a Parkinson Rat Model

N. Prudon, L. Cordero-Espinoza, M. Abarkan, B. Gurchenkov, C. Morel, M. Lepleux, V. de Luca, N. Pujol, L. Milvoy, P. Morand, F. Moncaubeig, H. Wurtz, L. Poinçot, M. Demarco, A. Jonckeau, J. Plétenka, E. Luquet, K. Schmit, L. Piouceau, S. Guilbert, L. Manache-Alberici, M. Lanero, G. Dabee, T. Dufourd, J. Schroeder, K. Alessandri, E. Bezard, E. Faggiani, M. Feyeux (Bordeaux, France)

Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model

G. Tian, R. Zhou, J. Lu, W. Shi, R. Li, X. Guo (Xi'an, China)

Buspirone/zolmitriptan combination exerts synergistic reduction in dyskinesia without worsening Parkinson disease motor symptomatology

P. Lewitt, G. Stebbins, K. Christensen, M. Thomsen, R. Tan, A. Pretorius (Detroit, USA)

Carbidopa does not cause changes in QTc interval even at a supratherapeutic dose

R. Kleiman, J. Mickelson, R. Sanwo, C. Edwards, S. Fisher, H. Visser (South Gate, USA)

Case Report Increasing ‘On-time’ Using Mucuna pruriens Concomitantly with Traditional Levodopa/carbidopa Management

T. Denne (United States, USA)

Characterising early morning akinesia and off (EMO) using Parkinson’s kinetigraph: analysis from a two centre national database in Parkinson’s disease .

K. Poplawska-Domaszewicz, D. Trivedi, K. Ray Chaudhuri (Poznan, Poland)

Clinical benefit of Opicapone in patients with different Parkinson disease phenopytes. The OPTIMO study

MR. Luquin, C. Martin, I. Tegel, I. Pijuan, C. Moreno (Pamplona, Spain)

Clinical characteristics associated with early discontinuation of Levodopa-Carbidopa Intestinal Gel infusion in patients with advanced Parkinson Disease.

D. Rivero-Rodríguez, M. Morales-Casado, G. Tabar-Comellas, A. Diezma-Martín, P. Quintana-Castro, M. Ennazeh, N. López-Ariztegui (Toledo, Spain)

Clinical Response and Reduction in Medication Use After Deep Brain Stimulation Surgery in a Cohort of Parkinson’s Disease Patients in Colombia

T. Lopez Gonzalez, S. Poveda, M. Fonseca, P. Arango, O. Rojas, G. Monsalve, JC. Diez, J. Lobato, O. Bernal Pacheco (Bogotá, Colombia)

Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription

Y. Tai, S. Hsu, H. Kuo (Kaohsiung City, Taiwan)

Comparative analysis of opicapone and entacapone in the management of motor fluctuations in patients with Parkinson’s disease, from clinical trials to healthcare resource usage

D. Kremens, F. Amjad, S. Thakkar, B. Naderi, D. Martins, J. Rocha, G. Banisadr, S. Fisher (Wynnewood, USA)

Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study

D. Standaert, A. Fasano, F. Ory-Magne, D. Kern, O. de Fabregues, T. Oeda, D. Safarpour, Z. Baldwin, C. Yan, S. Wang, K. Onuk, P. Kukreja, L. Bergmann, V. Fung (Birmingham, USA)

Comparing Pramipexole and Ropinirole in the management of the tremor in Parkinson’s disease in the low-income country and environment of restricted medications.

B. Mukhammedaminov (Uzbekistan, Uzbekistan)

Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections

A. de Leon, O. Phokeawvarangkul, R. Bhidayasiri (Bangkok, Thailand)

Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis

R. Tang, R. Sun, S. Zhang, L. Chen (Shanghai, China)

Deep brain stimulation contact selection using Neurophysiology and Artificial intelligence

V. Lavu, J. Cagle, T. de Araujo, C. de Hemptinne, J. Wong (Gainesville, USA)

Deep Brain Stimulation of the Subthalamic Nuclei in Advanced Parkinson’s Disease what Effects on Motor Non-motor and Neuropsychological Functions a Monocentric Prospective Study with a 12-month Follow-up

V. Leclercq, B. Delsaut, V. Donckels, S. Dethy (Sint-Pieters-Leeuw, Belgium)

Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.

R. Singh, R. Bansal (Chandigarh, India)

Dose-dependent alterations of lysosomal activity and alpha-synuclein level in peripheral blood monocyte-derived macrophages and SH-SY5Y neuroblastoma cell line by upon inhibition of mTOR kinase activity

A. Bezrukova, K. Basharova, G. Baydakova, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain

Z. Zamfirov, D. Mugan, G. Ahluwalia (Annapolis, USA)

Effect of Tactile Cueing on Dual Task Performance in Parkinson’s Disease-A Systematic Review and Meta-Analysis

V. Azoidou, A J. Noyce, C. Simonet (London, United Kingdom)

Effectiveness of Subthalamic nucleus (STN) Deep Brain Stimulation Surgery (DBS) in patients with Parkinson’s Disease: A Patient and Caregiver reported outcome

S. Majumdar, S. Shee, S. Choudhury, J. Ganguly, P. Basu, N. Pandita, H. Kumar (Kolkata, India)

Effects of ATH434, a Clinical-Phase Small Molecule with Moderate Affinity for Iron, in a Parkinson’s Disease Model in Macaques

M. Bradbury, M. Aumann, D. Claassen, D. Finkelstein (Newark, USA)

Effects of ectopic dopamine D2 autoregulation of raphe-striatal projecting neurons on established L-DOPA-mediated behaviors in a hemiparkinsonian rat model

A. Centner, N. Lipari, C. Budrow, G. Mcmanus, I. Sandoval, K. Tseng, F. Manfredsson, C. Bishop (Binghamton, USA)

Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.

R. Cilia, F. Colucci, E. Cereda, V. Leta, M. Zibetti, M. Carecchio, S. Bonvegna, G. Calandra-Buonaura, R. Cerroni, R. de Micco, S. Tamburin, L. Magistrelli, F. Lena, M. Mascia, M. Picillo, G. Cossu, M. Marano, C. Leuzzi, C. Comi, A. Zampogna, C. Pellicano, S. Barca, V. Fioravanti, A. Pilotto, R. Zangaglia, M. Avenali, C. Sorbera, F. Di Biasio, F. Arienti, A. Nicoletti, C. Bagella, MC. Malaguti, A. Ranghetti, E. Caputo, D. Alimonti, E. Torre, GD. Oggioni, AE. Elia, N. Golfrè Andreasi, G. Devigili, B. Garavaglia, G. Imbalzano, T. Schirinzi, F. Cavallieri, A. Priori, M. Sessa, F. Tamma, M. Canesi, P. Solla, M. Zappia, A. Di Fonzo, L. Avanzino, A. Quartarone, EM. Valente, C. Pacchetti, A. Padovani, F. Valzania, A. Suppa, MT. Pellecchia, N. Modugno, M. Tinazzi, A. Tessitore, A. Stefani, P. Cortelli, IU. Isaias, A. Antonini, MC. Sensi, L. Lopiano, R. Eleopra (Milan, Italy)

Efficacy and Safety of Amantadine in Parkinson’s Disease with Dyskinesia and Motor Fluctuations: A Systematic Review and Meta-Analysis

S. Rujirussawarawong, S. Aungsumart, C. Kasemsuk, N. Limotai (Bangkok, Thailand)

Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis

G. Bolner, Y. Rossi, E. de Almeida, F. de Oliveira, V. Müller, L. Barbosa Lima, A. Rossato, G. Guindani Maia, A. Hilbig (Porto Alegre, Brazil)

Efficacy of Audiovisual Neuromodulation in the Treatment of Parkinson’s Disease

O. Alenikova, L. Parkhach, E. Bоsiakova, G. Zobnina (Minsk, Belarus)

Efficacy of Novel A2A/A1 Antagonist in Motor and non-Motor Symptoms of MPTP-Treated Macaques

J. Jung, Y. Lee, Y. Kim (Hwaseong-si, Gyeonggi-do, Republic of Korea)

Evaluating Clinical Practices of General Neurologists and Movement Disorder Specialists Based on 2020 AAN Parkinson Disease Quality Metrics

C. Marshall, P. Vaswani (Philadelphia, USA)

Evaluation of neuroprotective effects of doxycycline in a primate model of PD

L. Pedrosa, L. Leal, J. Muniz, E. Del-Bel, B. Gomes, L. Krejcová (Belém, Brazil)

Exercise for Parkinson’s: Building a Person-centered Resource through Partnership

R. Dolhun, L. Quinn (New York, USA)

Exidavnemab offers opportunities as a potential disease modifying therapy in several synucleinopathies

F. Eriksson, J. Fälting, E. Nordström, L. Söderberg, M. Johannesson, O. Zachrisson, P. Appelkvist, C. Möller, G. Osswald, M. Björklund, T. Odergren, E. Boström, E. Button, D. Sunnemark (Stockholm, Sweden)

Exploring Non-Invasive Wearable Devices in Home Settings for Assessment and Treatment of the Duration of ON and OFF State and Freezing of Gait in Parkinson’s Disease: A Case Study.

V. Azoidou, A. Noyce, C. Simonet, A. Mackett (London, United Kingdom)

Exploring the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In-Vitro Models

FAZ. Dustov, SEO. Seo (Tashkent, Uzbekistan)

Faecal Microbiota Transplant for Parkinson’s Disease: a Phase 1 Pilot Study to Establish Safety and Tolerability

M. de Sciscio, R. Bryant, S. Haylock-Jacobs, A. Day, S. Costello, T. Kimber (Adelaide, Australia)

Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach

S. Jain (Gandhinagar, India)

Gender Differences Following Bilateral STN DBS Surgery in Parkinson’s Disease

E. Israel, I. Dustin, D. Ehrlich (Bethesda, USA)

Hesperidin lessens rotenone induced Parkinson diseases angiogenesis in nigrostriatal neuronal death through the AMPK/FOXO3 Signaling pathway

DS. Singh (Allahabad, India)

Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease

J. Dupaul-Chicoine, S. Lavallée, N. Azevedo Portilho, L. Gong, M. Fournel, I. Ghosh, MR. Goldsmith, M. Ebert, O. Rousseau, L. Fader, JF. Marquis, S. Hedge (Saint-Laurent, Canada)

Identifying the Most Sensitive Patient-reported Items from the MDS-UPDRS that Predict Initiation of PD Medications in Early Disease

H. Zou, C. Goetz, G. Stebbins, T. Mestre, S. Luo (Durham, USA)

If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply

D. García-Meléndez, E. Gisbert Tijeras, B. Carmona Moreno, E. Botia Paniagua (Alcázar San Juan, Spain)

In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease

C. Mahapatra (Mumbai, India)

Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center

B. Delsaut, V. Leclercq, S. Dethy (La Louvière, Belgium)

Istradefylline therapy for dystonia in Parkinson’s disease

NAO. Kanzato, KOH. Nakachi, SAT. Mochizuki, (Okinawa, Japan)

Levodopa-Entacapone-Carbidopa Intestinal Gel in the treatment of advanced Parkinson’s disease: a two-year experience

J. Szász, V. Constantin, K. Orbán-Kis, S. Bataga, R. Neagoe, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmári (Targu Mures, Romania)

Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment In Parkinson’s Disease: A Single-Center Retrospective Chart Study

AA. Vanderplas (Leiderdorp, Netherlands)

Long term evaluation of gluten-free diet in Parkinson´s disease patients

H. Brožová, K. Poláková, T. Gentileová, M. Fialová, M. Kubjatková, J. Rusz, M. Sap, M. Kuzma, H. Pelantová, M. Jandová, D. Funda (Prague, Czech Republic)

Longitudinal Changes in Quality of Life After Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease

T. Yamamoto, Y. Yamanaka, S. Hirano, A. Sugiyama, N. Araki, Y. Higuchi, S. Kuwabara (Chiba, Japan)

Moderators of aerobic exercise effects on motor symptoms in patients with Parkinson’s disease: a systematic review and meta-analysis

R. Kim, N. Kang (Seoul, Republic of Korea)

Motor Impact of Fasting in Parkinson’s Disease Patients: An overview

N. Kouki, M. Messelmani, N. Kouki, H. Derbali, J. Zaouali, R. Mrissa (tunis, Tunisia)

Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel

M. Morales-Casado, G. Tabar-Comellas, E. Gisbert-Tijeras, DD. García-Meléndez, J. Domínguez-Bértalo, D. Rivero-Rodríguez, N. López-Ariztegui (Toledo, Spain)

Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson’s Disease-Like Motor and non-motor Symptoms in Zebrafish

KHA. Aran (Moga, India)

Neuroprotective role of baicalein via autophagy mediated modulation of associated motor proteins in experimental animals of Parkinson disease

D. Khatri, P. Naren (Hyderabad, India)

Neurotinib, a Brain Penetrant c-Abl Inhibitor, Prevents Activation and Phosphorylation of c-Abl Kinase and Alpha-Synuclein

N. Tayebi, B. Berhe, B. Aleksandra, J. Lichtenberg, A. D'Souza, M. Henderson, T. Chen, A. Alvarez, S. Zanlungo, M. Cookson, J. Marugan, E. Sidransky (Bethesda, USA)

Nocturnal Hypertension in Parkinson’s Disease. The Flip Side of a Tainted Coin

D. Wilson, M. Hagens, S. Nagaratnam, V. Fung (Sydney, Australia)

Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease

Z. Afshari, N. Nguyen, M. Afshari (Glenview, USA)

One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease

V. Lavu, J. Dwarampudi, Q. Yuan, F. Sarmento, T. de Araujo, V. Garg, J. Wong (Gainesville, USA)

Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.

L. Lopez Manzanares, J. Garcia Caldentey, R. Garcia-Ramos, M. Cerdan Sanchez, B. Solano Vila, G. Castilla-Fernandez, I. Pijuan Jimenez, I. Tegel Ayuela (Madrid, Spain)

Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion

M. Minar, I. Straka, Z. Kosutzka, Z. Andre (Bratislava, Slovakia)

Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film

L. Wojtecki, F. Moreira, E. Cubo, M. Fonseca, G. Harrison-Jones, C. Denecke Muhr (Düsseldorf, Germany)

Palliative Care in Advanced Parkinson’s Disease: Descriptive Analysis and Symptom Impact

C. Armengol-García, J. Hartmann-Nava, D. Martínez-Ramírez (Monterrey, Mexico)

Peri-Electrode Edema after Deep Brain Stimulation Implantation – Case Report and Literature Review

M. Marchiori, L. Packer, R. Pessoa, N. Martins, A. Schilling, M. Brunet (Brazil)

Pharmacokinetic-Pharmacodynamic Modeling of Amantadine Extended-Release Capsule Effects on Dyskinesia in Parkinson Disease

Z. Wang, R. Gomeni, R. Pahwa, R. Hauser, A. Formella, M. Grall, H. Upadhyaya, J. Rubin (Rockville, USA)

Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa

YR. Han, S. Stodtmann, M. Rosebraugh (North Chicago, USA)

Pre-treatment with Methanolic Extract Mucuna pruriens Seeds Attenuates Serotonin Gene Depletion, Motor Dysfunction and Anxiogenic Responses in a Rat Model of Parkinsonism

A. Obajuluwa, B. Laoye, J. Okwuaka, T. Obajuluwa, J. Lech, A. Oremosu (Ado -Ekiti, Nigeria)

Prediction of The Monopolar Review in Deep Brain Stimulation for Parkinson’s Disease using Imaging

V. Lavu, M. Godhala, T. Batchali, S. Aghili-Mehrizi, J. Wong (Gainesville, USA)

Pregnancy in Parkinson’s disease: Five cases

C. Armas, Y. Núñez, G. Gushiken, C. Cosentino (Lima, Peru)

Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents

P. Kukkle, L. Kalia, A. Habib, P. Jagota, R. Ojha, R. Kandadai, S. Desai, M. Caldera, D. Sirisena, D. Garg, T. Mestre, R. Neupane, S. Maytharakcheep, K. Sanyawut, R. Borgohain (Bangalore, India)

Recruitment of Ethnoracially Diverse Participants for Disease-Modifying Drug Trials in Parkinson’s Disease: Are We Doing It Right? A Systematic Review and Meta-Analysis.

F. Reis Rodrigues, E. Pasqualotto, G. Ribeiro, J. M. Couto, E. Bayram, M. Ushe, D. Di Luca (Vicosa, Brazil)

Relationships of blood Vitamin B12 and Homocysteine with Parkinson’s Disease Progression in 3 Contemporary Clinical Trials

C. Christine, P. Auinger, E. Forti, L. Tat, N. Cannizzaro, D. Oakes, R. Green (San Francisco, USA)

Safety and Efficacy of Sublingual Apomorphine in Parkinson’s Patients with or without Concomitant Dopamine Agonists Use

D. Santos Garcia, W. Jost, M. José Martí, M. Fonseca, C. Denecke Muhr, I. Pijuan (A Coruña, Spain)

Spray with Nasal Mucoadhesive Microspheres for Treating Parkinsonism.

S. Jain (Gandhinagar, India)

Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease

L. Ponsati, S. Hansen, M. Scharff, H. Klitgaard, S. Kauppinen, E. Bezard, J. Erler (København SV, Denmark)

The challenge to prevent Parkinson’s Disease with a new in vitro approach

C. Dalla Verde, S. Gazzin, C. Tiribelli (Trieste, Italy)

The Effect of Modulating Alpha-synuclein Aggregation on Clinical Outcome in the Presence of Standard-of-care Dopaminergic Therapy in Parkinson’s Disease. A Quantitative Systems Pharmacology Approach.

H. Geerts, S. Short (Princeton, USA)

The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease

O. Phokaewvarangkul, R. Bhidayasiri (Bangkok, Thailand)

The impact of multimodal forms of art therapy on treatment outcomes and quality of life in Parkinson’s disease

L. čondić Jurjević, S. Telarović (Sisak, Croatia)

The international validation of the “Stepped Care” toolkit for comprehensive real life clinical care: bridging massive unmet need in care of Parkinson’s disease.

K. Poplawska-Domaszewicz, MA. Qamar, L. Batzu, A. Shalash, Y. Lau, C. Falup-Pecurariu, A. Rekik, I. Boura, C. Spanaki, J. Chacko, C. Rodriguez-Blazquez, D. Urso, R. van Coller, D. Trivedi, V. Leta, W. Kozubski, S. Michalak, J. Slawek, C. Padmakumar, S. Gangadharan, K. Koh, C. Lazacano-Ocampo, A. Sauerbier, H. Dafsari, Y. Tsuboi, N. Mostyn, K. Ray Chaudhuri (Poznan, Poland)

The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases

D. Willbold (Jülich, Germany)

Trends in Physiotherapy Interventions and Medical Costs for Parkinson’s Disease in South Korea, 2011–2020

DW. Ryu, MJ. Lee, JS. Park, DL. Yoo, SM. Cheon ()

TrkB modulator OT-003 reduces dopaminergic cell loss, mitochondrial stress, alpha-synuclein aggregation and motor dysfunction in Parkinson’s disease models.

T. Pfeiffer, M. Ho, E. Duckworth, L. Tear, Z. Zahariev, L. Khederlarian, A. Plowright (Sevenoaks, United Kingdom)

Using Algorithm Guided Programming to Treat Parkinson’s Disease Patients Implanted with Deep Brain Stimulation

C. Luca, Y. Lin, K. Su, J. Jagid, V. Torres, R. Shivacharan, L. Moore (Miami, USA)

Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease

R. Gordon, K. Bhatt, N. Jayabalan, N. Birch, A. Lehn, B. Oronsky, S. Caroen, T. Reid (Brisbane, Australia)

Writing rehabilitation in parkinson’s disease (pd) through a virtual workshop

F. Echeverria, P. Sanchez Diaz, S. Revellini, G. Costa, G. Ziegler, S. Rodriguez Quiroga, T. Arakaki, N. Garretto (Buenos Aires, Argentina)